Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma

NCT07690189 is registered in ClinicalTrials.gov with TeneoSeven, Inc. as lead sponsor.

NCT NCT07690189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07690189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma
Lead sponsor
TeneoSeven, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 29, 2026
Completion date
February 28, 2029
Enrollment
90 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory ovarian carcinoma